Charles River Laboratories Intl. Inc vs Motorola Solutions Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Motorola Solutions Inc trades at $444.18 (market cap $74.00B). The key difference: Motorola Solutions Inc is far larger — about 5.2× Charles River Laboratories Intl. Inc's market cap, and Motorola Solutions Inc pays a 1.08% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Motorola Solutions Inc for 100 Days on average.
| CRL | MSI | |
|---|---|---|
Market Cap | $14.23B | $74.00B |
Volume | 1,176,885 | 722,147 |
Sector | Health | Technology |
52-Week High | $310.77 | $491.24 |
52-Week Low | $149.93 | $363.83 |
Typical Hold Time | 33 Days | 100 Days |
Enterprise Value | $17.06B | $82.90B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Motorola Solutions (MSI) trades at $447.12, down 0.3% with a bearish technical signal despite strong fundamentals. The company shows robust revenue growth from $11.68B in 2025 to $12.2B projected for 2026, with net income margins above 17%. Recent developments include a $1.5B D-Fend acquisition, a $61.3M US Navy contract, and a $2B share repurchase authorization. Analyst consensus remains strongly bullish with a $525.86 price target, though technical indicators show selling pressure near current levels.
MSI presents a compelling growth story with expanding defense contracts and strategic acquisitions driving revenue. However, elevated valuation ratios (P/E 35.23, P/S 6.14) and negative cash flow trends pose risks. The stock offers 17.6% upside to consensus target, but investors should monitor execution of recent acquisitions and cash flow improvement for sustained momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →